We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Cel Sci Corporation New | AMEX:CVM | AMEX | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.04 | 2.82% | 1.46 | 1.47 | 1.41 | 1.44 | 57,551 | 20:02:41 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): January 13, 2016
Colorado 0-11503 84-0916344 -------------------- ------------------ ----------------- (State or other jurisdiction (Commission File No.) (IRS Employer of incorporation) Identification No.) |
Registrant's telephone number, including area code: (703) 506-9460
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14c))
Item 1.01 Entry Into a Material Definitive Agreement
On January 13, 2016 the Company sold 3,000,000 shares of its common stock and 3,000,000 warrants to the de Clara Trust for $1,110,000. The de Clara Trust is controlled by Geert Kersten, the Company's Chief Executive Officer and a director. Each warrant allows the de Clara Trust to purchase one share of the Company's common stock at a price of $0.37 per share at any time on or before January 13, 2021.
The Company's directors have determined that the terms of the Series N warrants held by the de Clara Trust will not be changed and will have the same terms as were in existence prior to January 13, 2016.
Item 9.01 Financial Statements and Exhibits. Exhibit Description ------- ----------- 5 Opinion of Hart & Hart, LLC 10(fff) Subscription Agreement 10(ggg) Form of Warrant (Series X) 23 Consent of Hart & Hart, LLC |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 15, 2016 CEL-SCI CORPORATION By: /s/ Patricia B. Prichep -------------------------------- Patricia B. Prichep, Senior Vice President of Operations |
1 Year Cel Sci Chart |
1 Month Cel Sci Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions